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ABSTRAEC Sera from healthy individuals and patients with
infectious mononucleosis, Burkitt lymphoma, nasopharyngeal
carcinoma, or other malignancies were examined for their ca-
pacity to neutralize Epstein-Barr virus (EBV)induced DNase
activity. Sera were found that neutralized the EBV DNase but
not herpes simplex virus type 1 or type 2 DNases, and vice versa.
Sera from 46 of the 49 patients withnasopharyngeal carcinoma
examined (94%) neutralized >6 units of EBV DNase per ml of
serum. In contrast, only 19% of 47 patients with Burkitt lym-
phoma, 12% of 183 patients with other malignancies, 4% of 58
patients with infectious mononucleosis, and none of 101 healthy
individuals had such levels of neutralizing activity. The neu-
tralizing factor was found in the IgG fraction derived from
nasopharyngeal carcinoma sera. There was no correlation be-
tween the concentration of these antibodies and the titers of IgG
and IgA antibodies to the EBV capsid antigen, the early antigen
complex, or the EBV-associated nuclear antigen.
The Epstein-Barr virus (EBV) is closely associated with naso-
pharyngeal carcinoma (NPC). Patients beyond the initial stage
of this tumor generally show high titers of IgG and IgA anti-
bodies to the EBV capsid antigen (VCA) and to the diffuse (D)
component of the early antigen complex (1-8). Biopsies of the
tumor regularly reveal the presence of EBV DNA (9-11), and
the carcinoma cells express the EBV-associated nuclear antigen
(EBNA) (12-15). The antibody spectrum and titers increase
with the stage of the disease; i.e., the total tumor burden (3, 5,
8, 16). Correspondingly, the antibody titers decline gradually
after effective therapy of NPC, so that the EBV-specific sero-
logic tests may serve to monitor the success of treatment (8).
Relapses or metastases are heralded by rising antibody titers
months before they become clinically evident (8).
Recently, it was demonstrated that EBV is capable of in-
ducing a virus-specific DNase upon superinfection of Raji cells
or upon exposure of somatic hybrid cells to IdUrd (17). This
induced DNase differs in its physical and immunogenic
properties from DNases induced in appropriate cells by other
herpes group viruses (17, 18). Because the DNases induced by
herpes simplex virus (HSV) type 1 or 2 are capable of eliciting
specific antibody responses in patients with HSV infections (19),
we assayed sera from various patients and controls for the
presence of antibody against the EBV-specific DNase. The
serum donors included healthy individuals with or without past
exposure to EBV and patients with infectious mononucleosis,
Burkitt lymphoma, NPC, or other malignant diseases. The data
to be presented show a high frequency of strong anti-EBV
DNase activity in sera from patients with NPC. The degree of
anti-EBV DNase activity does not correlate with EBV-specific
antibody titers to early antigen, VCA, or EBNA.
MATERIALS AND METHODS
Preparation of Cellular Extract. Raji cells were maintained
in RPMI 1640 medium supplemented with 10% (vol/vol) fetal
calf serum, 100 units of penicillin per ml, 100 pug of strepto-
mycin per ml, 1 ,ug of fungizone per ml, 10 units of mycostatin
per ml, and 0.075% NaHCO3 in 16-oz. glass prescription bottles
(1 oz. = 29.57 ml). They were infected with cell-free EBV de-
rived from HR-I cultures by described procedures (17) and
harvested 48 hr after infection. One milliliter of extraction
buffer containing 2 mM Mg2+-ATP, 0.4 mM KC1, 3 mM di-
thiothreitol, and 50 mM Tris.HC1, pH 7.5, was added to 2 X 107
cells. The cells were frozen and thawed four times and then
centrifuged for 3 min at 40C in a Beckman model B microfuge.
The supernatant was used for determination of DNase ac-
tivity.
Enzyme Assay. The assay procedures for EBV DNase ac-
tivity were the same as described for exonuclease (18). One unit
of DNase activity is defined as the amount of enzyme that
converts 1 ,g of double-stranded DNA to acid-soluble material
in 10 min at 370C. The specific activity of the DNase used was
30 units/mg of protein, and the activity of DNase in mock-
infected Raji cells was t1 unit/mg.
Human Sera. The sera had been collected and tested pre-
viously for other studies and had been kept at -20'C. They
included 101 sera from healthy donors (27 anti-VCA negative,
74 positive), 58 sera from infectious mononucleosis patients, 47
sera from Burkitt lymphoma patients, 49 sera from NPC pa-
tients, and 31 sera from patients with Hodgkin disease, malig-
nant lymphomas, or other cancers.
Determination of Anti-EBV DNase Activity. A 0.1-unit
sample of DNase from crude homogenates of EBV-superin-
fected Raji cells in a total volume of 5Ml was incubated with 5
,Ml of serum at room temperature for 20 min. The activity of
EBV DNase was then determined as described (17). The dif-
ference of activity in the presence and absence of serum was
calculated and the anti-DNase antibody activity was expressed
as the units of DNase activity neutralized by 1 ml of
serum.
Determination of Antibodies Against Other EBV-Specific
Antigens. All sera were titrated for IgG antibodies and, when
indicated, IgA or IgM antibodies to VCA and to the diffuse (D)
and restricted (R) components of the EBV-determined early
antigen complex by indirect immunofluorescence. They were
titrated for antibodies to EBNA by anti-complement immu-
nofluorescence. The techniques have been described (7, 20-
22).
Abbreviations: EBV, Epstein-Barr virus; EBNA, EBV-associated nu-
clear antigen; NPC, nasopharyngeal carcinoma; HSV-1 and HSV-2,
herpes simplex virus types 1 and 2, respectively; VCA, virus capsid
antigen.
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Table 1. Specificity of antiviral DNase activity in human serum
Antiviral DNase activity,
units neutralized/ml serum
Serum added HSV-1 HSV-2 EBV
1 0 0 0
2 20 38 0
3 1* 0 9
4 1* 5 0
Crude cellular extract from HSV-1 (KOS)- and HSV-2 (333)-in-
fected KB cells (18) and from EBV-infected Raji cells were used for
this study.
* Within the range of nonspecific neutralization.
Purification of IgG from Serum. Three milliliters of serum
from patients with NPC were dialyzed overnight against 20
mM potassium phosphate buffer (pH 8.0) containing 0.02%
sodium azide and then placed on a DEAE-Affi-Gel Blue (Bio-
Rad) column (1.5 X 13 cm) that had been equilibrated with the
same buffer. The highly purified IgG fraction was collected in
the void volume by washing the column with buffer. The total
recovery of anti-EBV DNase activity was nearly 100%. The
purity of the IgG fraction was examined by disc electrophoresis
by published procedures (23). One major and one minor protein
band were observed in the gel. The major band had the same
mobility as IgG. The minor band had the same mobility as
transferrin.
RESULTS
Demonstration of Antibody Specific for EBV-Induced
DNase. Sera from four individuals demonstrate the specificity
of the neutralizing activity against enzymes derived from
HSV-1-, HSV-2-, and EBV-infected cells (Table 1). Serum no.
1 had no activity against any of the virus-specific DNase ac-
tivities. Serum no. 2 neutralized both the HSV-1 and HSV-2
DNases, although to different extents, but not the EBV DNase,
whereas serum no. 3 had strong activity against EBV but not
against HSV-1 and HSV-2 DNases.
In order to determine whether the inhibition of the EBV-
induced DNase was due to antibody or to a nonspecific factor,
several strongly positive sera were pooled and the IgG fraction
was separated by DEAE-Affi-Gel Blue column chromatogra-
phy. The anti-EBV DNase activity of serial dilutions of the









Table 2. Incidence of antibodies against EBV-induced DNase in
human sera
Anti-EBV DNase activity*
No. of (units neutralized/ml serum)
Source of sera patients <3 3-6 >6
Healthy donorst 101 94 (93) 7 (7) 0 (0)
Infectious mononucleosis 58 52 (90) 2 (3) 4 (7)
NPC 49 2 (4) 1 (2) 46 (94)
Burkitt lymphoma 47 28 (60) 10 (21) 9 (19)
Other lymphomast 31 23 (73) 3 (10) 5 (17)
Leukemias§ 49 37 (76) 5 (10) 7 (14)
Other carcinomas1 103 90 (87) 3 (3) 10 (9)
* Values are the no. of patients whose sera had the indicated activity.
Numbers in parentheses indicate the percentage of sera.
t Seventy-five subjects were anti-VCA positive and 26 subjects were
negative.
Five patients with malignant lymphoma and 26 patients with
Hodgkin disease.
§ Ten patients with chronic lymphocytic leukemia and 39 patients
with acute myelocytic leukemia.
Five patients with carcinoma of the tonsil and 98 patients with
prostate carcinoma.
DNase. The results (Fig. 1) showed a dose-response relationship.
The IgG fraction of pooled sera isolated from healthy indi-
viduals in a similar fashion showed no neutralization of EBV
DNase activity (data not shown).
Frequency and Concentration of Antibody to EBV-In-
duced DNase. Table 2 and Fig. 2 summarize the data observed
with sera from healthy donors and from several groups of pa-
tients. Of 101 healthy donors studied, 27 had not yet been in-
fected with EBV; they had no antibodies to VCA or EBNA. Sera
from seven of these individuals nevertheless neutralized be-
tween 1 and 2.5 units of EBV DNase. For this reason, only
neutralization of _3 units of enzyme can be considered due to
a virus-specific antibody. Taking neutralization of 6 units of
EBV DNase as strong reactivity, none of the 74 sera from
healthy anti-VCA-positive individuals, only 4 of 58 (7%) in-
fectious mononucleosis sera, 9 of 47 (19%) Burkitt lymphoma
sera, and 22 of 183 (12%) sera from other patients fell into this
category. In contrast, 46 of the 49 (94%) sera from NPC patients
neutralized >6 and as many as 18 units of the enzyme.
Correlation of Anti-EBV DNase Activity with Other
EBV-Specific Antibodies in Serum from Patients with NPC.
In Fig. 3, various EBV-specific antibody titers in sera from NPC
patients are plotted against the anti-EBV DNase activity. No
correlation was evident between the anti-EBV DNase activity
and the other types of EBV-specific antibodies.
n 27 75 58 47 49 103 31 49
1 3 10 30
IgG, -fold dilution
100
FIG. 1. Dose-response relationship of anti-EBV DNase activity
and IgG fraction purified from sera of NPC patients.
FIG. 2. Concentration of antibody to EBV-induced DNase in sera
from healthy individuals and patients with different conditions. The
ordinate indicates the number of EBV DNase units neutralized. a,
Healthy donor, anti-VCA negative (<1:10); b, healthy donor, anti-
VCA positive; c, infectious mononucleosis; d, Burkitt lymphoma; e,
NPC; f, other carcinomas; g, other lymphomas; and h, leukemias.
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FIG. 3. Lack of correlation between the degree of anti-EBV DNase activity and the titers ofIgG or IgA antibodies to VCA (A), the D (diffuse)
component of the early antigen complex (A), and EBNA (B). Serum dilutions of 10 and <10 have been combined. For VCA and EBNA, n =
45; for D (IgA), n = 38; and for D (IgG), n = 40.
DISCUSSION
The high incidence and high concentration of anti-EBV DNase
activity in sera from patients with NPC demonstrated in this
communication appear to be another outstanding feature of
this malignancy and further support the close relationship be-
tween NPC and EBV. This anti-DNase activity is virus specific,
as evident from Table 1. In general, most sera from healthy
individuals have anti-HSV-1 DNase activity, but, as seen in
Table 2, none has high titers of anti-EBV DNase activity.
Burkitt lymphoma is, like NPC, intimately associated with EBV
(24), but the incidence and concentration of anti-EBV DNase
activity in sera from such patients are much lower than ob-
served in NPC. If we assume that the presence of anti-EBV
DNase activity is due to the continuous expression of EBV
DNase, the degree of this expression would clearly be less
pronounced in Burkitt lymphoma (lymphoma cells) than in
NPC (undifferentiated carcinoma cells).
A question may be raised concerning the degree of purity
of the EBV DNase used as antigen in our study. We have not
been able to purify EBV DNase from EBV-superinfected Raji
cells to the same degree as we purify HSV-1 or HSV-2 DNase
from infected cells. Based on our past experience, the purity
of antigen may not be a problem because the interaction of
antibodies against either HSV-1 or HSV-2 DNase was similar
whether purified or crude preparations were used. Further-
more, because mock-infected Raji cell control extracts have 97%
less DNase activity, the predominant species of DNase in
EBV-superinfected Raji cells is virus specific (17).
We are tiow collecting sera from NPC patients at different
stages of the disease and before and after treatment, as well as
sera from high-risk populations. Study of these sera may provide
information on the potential usefulness of the degree of anti-
EBV DNase activity in determining the prognosis of the pa-
tients.
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